• Mashup Score: 3

    Glioblastoma (GBM) is the most common and malignant primary brain tumor affecting adults and remains incurable. The mitochondrial coiled‑coil‑helix‑coiled‑coil‑helix domain‑containing protein 2 (CHCHD2) has been demonstrated to mediate mitochondrial respiration, nuclear gene expression and cell migration; however, evidence of this in GBM is lacking. In the present study, it was hypothesized that CHCHD2 may play a functional role in U87 GBM cells expressing the constitutively active epidermal growth factor receptor variant III (EGFRvIII). The amplification of the CHCHD2 gene was found to be associated with a decreased patient overall and progression‑free survival. The CHCHD2 mRNA levels were increased in high‑vs. low‑grade glioma, IDH‑wt GBMs, and in tumor vs. non‑tumor tissue. Additionally, CHCHD2 protein expression was greatest in invasive, EGFRvIII‑expressing patient‑derived samples. The CRISPR‑Cas9‑mediated knockout of CHCHD2 in EGFRvIII‑expressing U87 cells resulted in an altered m

    Tweet Tweets with this article
    • Study shows mitochondrial protein plays key role in #glioblastoma and therapeutic resistance @UofIllinois https://t.co/7TcVCbQ1yz https://t.co/96I9RL5ZIU

  • Mashup Score: 0

    We are delighted to announce the official start of LEGATO, a pragmatic phase III clinical trial focusing on recurrent Glioblastoma.

    Tweet Tweets with this article
    • 🎉We are delighted to announce the official start of @HorizonEU funded @Legato_Horizon #ClinicalTrial on recurrent #Glioblastoma🧠, in collaboration with Syreon Research Institute. More: https://t.co/IYT8BJAxTE @EU_Commission #LEGATO_Horizon #HorizonEurope #EUCancerMission https://t.co/3f4qIfzdMW